Literature DB >> 9761574

Percutaneous endoluminal treatment of iliac occlusions: long-term follow-up in 105 patients.

M Henry1, M Amor, G Ethevenot, I Henry, B Mentre, K Tzvetanov.   

Abstract

PURPOSE: To evaluate the long-term results of percutaneous recanalization techniques in occluded iliac arteries.
METHODS: Percutaneous recanalization was attempted in 105 patients (97 men; mean age 56 years, range 34 to 80) with iliac occlusions using thrombolysis (n = 15), excimer laser (n = 4), mechanical thrombectomy (n = 16), balloon angioplasty alone (n = 23), and angioplasty plus stenting (n = 69). The majority of lesions (n = 72) were in the common iliac artery (CIA); 33 were in the external iliac artery (EIA).
RESULTS: The primary recanalization rate was 88% (92/105) independent of location (EIA: 90%, CIA: 86%) and lesion length, but dependent on age of thrombus (< 3 months: 100%, > 3 months: 79%, p < 0.02). Complications included 5 (4.8%) cases of distal embolism treated by thromboaspiration or Fogarty balloon embolectomy. Seven (6.7%) early thromboses were treated surgically. Primary and secondary patency rates were calculated at 6 years for all 105 cases and for the 92 recanalized lesions using life-table analysis. Overall, primary patency was 52% (CIA: 58%, EIA: 34%) and secondary 66% (CIA: 74%, EIA: 40%). Lesions < 6 cm had a primary patency of 70%, while those > 6 cm had a 31% rate (p < 0.01). Secondary patencies were 86% and 42%, respectively (p < 0.01). Among recanalized lesions, the primary patency was 61% (CIA: 69%, EIA: 38%) and secondary 77% (CIA: 88%, EIA: 45%; p < 0.05). Lesions < 6 cm had a primary patency rate of 72%, while longer lesions had a primary rate of 44% (p < 0.04); secondary patencies were 89% and 59%, respectively (NS). Primary patency without stent was 57% and with stent 65% (NS); secondary patency without stent was 71% and with stent 82% (NS).
CONCLUSIONS: Percutaneous recanalization of iliac occlusions represents a true alternative to vascular surgery and a first-line treatment option. Stents have a tendency to improve long-term results and are recommended for routine use in chronic iliac occlusions.

Entities:  

Mesh:

Year:  1998        PMID: 9761574     DOI: 10.1177/152660289800500307

Source DB:  PubMed          Journal:  J Endovasc Surg        ISSN: 1074-6218


  7 in total

1.  Peripheral arterial disease: Epidemiology, natural history, diagnosis and treatment.

Authors:  Gurbir Dhaliwal; Debabrata Mukherjee
Journal:  Int J Angiol       Date:  2007

2.  Primary stent placement for iliac artery chronic total occlusions.

Authors:  Yuka Kondo; Alan Dardik; Akihito Muto; Jun Koizumi; Masayasu Nishibe; Toshiya Nishibe
Journal:  Surg Today       Date:  2010-04-28       Impact factor: 2.549

3.  A dual (brachial and contralateral femoral) approach for subintimal angioplasty of long ilio-femoral occlusive disease including the iliac ostium.

Authors:  Jong Shin Woo; Sang Jin Ha; Weon Kim
Journal:  Korean Circ J       Date:  2010-02-23       Impact factor: 3.243

Review 4.  State of the art: which stent for which lesion in peripheral interventions?

Authors:  M Henry; C Klonaris; M Amor; I Henry; K Tzvetanov
Journal:  Tex Heart Inst J       Date:  2000

5.  DISCOVER: Dutch Iliac Stent trial: COVERed balloon-expandable versus uncovered balloon-expandable stents in the common iliac artery: study protocol for a randomized controlled trial.

Authors:  Joost A Bekken; Jan Albert Vos; Ruud A Aarts; Jean-Paul P M de Vries; Bram Fioole
Journal:  Trials       Date:  2012-11-19       Impact factor: 2.279

6.  Multiple thromboembolism with multiple causes in a 69-year-old woman: a case report.

Authors:  Luigi Iuliano; Maria Misuraca; Alessandro Varroni; Massimo Raponi; Marco Massucci; Alessandro Pagnanelli; Giuseppe Cimino; Giovanni Bertoletti
Journal:  J Med Case Rep       Date:  2011-05-14

7.  Strategies for successful percutaneous revascularization of chronic total occlusion of the femoropopliteal arteries when the antegrade passage of a guide wire fails.

Authors:  Hui Jin Lee; Sang Woo Park; Il Soo Chang; Hae Jeong Jeon; Jeong Hee Park
Journal:  Korean J Radiol       Date:  2012-06-18       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.